Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Should Adagio Say Goodbye to Its COVID-19 Hopes?

TheMotleyFool

0 0

Should Adagio Say Goodbye to Its COVID-19 Hopes?

It wasn't very long ago that Adagio Therapeutics (NASDAQ: ADGI) thought it could have a big winner on its hands with experimental COVID-19 antibody therapy ADG20. However, the company's latest data has changed the outlook considerably. In this Motley Fool Live video recorded on Dec. 15, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Adagio should say goodbye to its COVID hopes.

Source Fool.com

Like: 0

ADGI

Share